Figure 1. Enrollment and Outcomes.

dMMR indicates mismatch repair deficient; MMRp, mismatch repair proficient; MMRunk, mismatch repair status unknown; MSI-H, microsatellite instability–high; POLE, polymerase epsilon.

^aSixteen patients had no measurable disease per blinded independent central review (BICR) at baseline and were excluded from the efficacy population.

^bAll patients with dMMR and MSI-H or POLE-altered solid tumors who had received at least 1 dose of dostarlimab, had at least 1 BICR-confirmed measurable lesion at baseline, and had the opportunity to be followed up for at least 6 months as of the data cutoff date were included in the efficacy population, regardless of whether the patient had a postbaseline tumor assessment.

^cTotal of 327 patients with dMMR solid tumors (including 2 who were also POLE-altered).

^dTotal of 106 patients with dMMR solid tumors (including 2 who also had POLE alterations).

^eSeven patients with MMR unknown/MSI-H tumors or MMRp tumors (including 2 who had POLE alterations).